<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345253</url>
  </required_header>
  <id_info>
    <org_study_id>113750</org_study_id>
    <nct_id>NCT01345253</nct_id>
  </id_info>
  <brief_title>GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia</brief_title>
  <official_title>GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of belimumab in addition to
      standard therapy compared to placebo in subjects in Northeast Asia with systemic lupus
      erythematosus (SLE) over a 52 week period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the efficacy and safety of belimumab 10mg/kg
      administered intravenously (IV) every 4 weeks compared to placebo, in patients with SLE when
      added to standard of care therapy, as measured by the SLE Responder Index (SRI) at 52 weeks,
      defined by a composite endpoint using SELENA SLEDAI score, Physician's Global Assessment
      (PGA) and BILAG A and B organ domain scores.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 23, 2011</start_date>
  <completion_date type="Actual">September 21, 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase.</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI response is a composite index, defined as the percent of participants with &gt;=4 point reduction from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score and no worsening (increase of &lt; 0.30 points from Baseline) in physicians global assessment (PGA) and no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With &gt;=4 Point Reduction From Baseline in SELENA SLEDAI Score at Week 52 for Double-blind Phase.</measure>
    <time_frame>Baseline (Day 0) and Week 52</time_frame>
    <description>The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. The Baseline value of a variable is defined as the value of the variable measured at Day 0 prior to dosing. In case of multiple results on Day 0 prior to dosing, the latest result was used. If a Day 0 value was not available, the last available value prior to Day 0 was used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With SRI7 Response at Week 52 for Double-blind Phase.</measure>
    <time_frame>Baseline (Day 0) and Week 52</time_frame>
    <description>SRI7 response is defined as the percent of participants with &gt;=7 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of &lt; 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days of Daily Prednisone Dose &lt;=7.5 mg/Day and/or Reduced by 50 Percent From Baseline Over 52 Weeks for Double-blind Phase.</measure>
    <time_frame>Week 52</time_frame>
    <description>Number of days of daily prednisone dose &lt;=7.5 mg/day and/or reduced by 50 percent over time through each scheduled visit during the blinded period were compared between belimumab and placebo using Rank ANCOVA model which was used for comparing belimumab and placebo. The independent variables in the model included treatment group, Baseline prednisone dose level, country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). This analysis was perfomed on the participants who used prednisone &gt;7.5 mg/day at Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe SLE Flare Index (SFI) Flare Over 52 Weeks for Double-blind Phase.</measure>
    <time_frame>52 weeks</time_frame>
    <description>Time to first severe SLE flare is defined as the number of days from first treatment until the participant had an event (event date-treatement start date +1). If a participant had a severe SFI flare and received protocol restricted medication then the event date was the earliest of the first severe SFI flare date, and the treatment failure date. Analysis of severe SFI flare was performed on the modified SELENA SLEDAI SLE flare index in which the modification excluded severe flares that were triggered only by an increase in SELENA SLEDAI score to &gt;12. Analysis was from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving SLE SRI Response Rate for Open-label (OL) Phase</measure>
    <time_frame>Weeks 24 and 48 for Years 2, 3, 4, 5 and 6</time_frame>
    <description>SRI response is a composite index, defined as the percent of participants with &gt;=4 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of &lt; 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at time of assessment. Excludes participants with a SELENA SLEDAI score &lt;4 at baseline. Participants randomized to belimumab in double-blinded (DB) phase, Baseline is last available value before first belimumab dose received in DB phase. Participants randomized to placebo in DB phase, Baseline is last available value before receiving first belimumab dose in OL phase. Observed case data are presented.Year 6 Week 48 is the Exit Visit obtained by slotting the Exit Visit to Week 48. A SELENA SLEDAI score of 0 (no lupus activity) and a score of 105 (maximum). PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">709</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Belimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab</intervention_name>
    <description>10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.</description>
    <arm_group_label>Belimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years and older.

          -  Have a clinical diagnosis of SLE according to the American College of Rheumatology
             (ACR) classification criteria.

          -  Have active SLE disease.

          -  Have positive anti-nuclear antibody (ANA) test results.

          -  Are on a stable SLE treatment regimen.

          -  Females of childbearing age are willing to use appropriate contraception

        Exclusion Criteria:

          -  Have received treatment with any B cell targeted therapy at any time.

          -  Have received a biologic investigational agent in the past year.

          -  Have received 3 or more courses of systemic corticosteroids in the past year.

          -  Have received intravenous (IV) cyclophosphamide within 180 days prior to Day 0.

          -  Have severe lupus kidney disease.

          -  Have active central nervous system (CNS) lupus.

          -  Have had a major organ transplant.

          -  Have significant unstable or uncontrolled acute or chronic diseases or conditions not
             due to SLE.

          -  Have a planned surgical procedure.

          -  Cancer within the last 5 years, except for adequately treated skin cancer, or
             carcinoma in situ of the uterine cervix.

          -  Have required management of acute or chronic infections in the past 60 days.

          -  Have current drug or alcohol abuse or dependence.

          -  Have a historically positive test, or test positive at screening for HIV, Hepatitis B,
             or Hepatitis C.

          -  Have an IgA deficiency.

          -  Have severe laboratory Abnormalities.

          -  Have had anaphylactic reaction to X-ray contrast agents or biologic agents.

          -  Suicidal behavior or ideation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510630</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Xian</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650101</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chiba</city>
        <zip>275-8580</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ehime</city>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-8619</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <zip>739-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hokkaido</city>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyogo</city>
        <zip>675-8545</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miyagi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <zip>857-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okayama</city>
        <zip>710-0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Okinawa</city>
        <zip>901-0243</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tochigi</city>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suwon, Kyonggi-do</city>
        <zip>443-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis. 2018 Mar;77(3):355-363. doi: 10.1136/annrheumdis-2017-211631. Epub 2018 Jan 2.</citation>
    <PMID>29295825</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2011</study_first_posted>
  <results_first_submitted>June 9, 2016</results_first_submitted>
  <results_first_submitted_qc>November 17, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 2, 2016</results_first_posted>
  <last_update_submitted>September 20, 2019</last_update_submitted>
  <last_update_submitted_qc>September 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLEDAI</keyword>
  <keyword>Asia</keyword>
  <keyword>placebo</keyword>
  <keyword>BLys</keyword>
  <keyword>PGA</keyword>
  <keyword>BILAG</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>SELENA</keyword>
  <keyword>Lupus</keyword>
  <keyword>SRI</keyword>
  <keyword>efficacy</keyword>
  <keyword>B cell</keyword>
  <keyword>SLE Flare Index</keyword>
  <keyword>belimumab</keyword>
  <keyword>safety</keyword>
  <keyword>phase III</keyword>
  <keyword>B lymphocyte</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study consisted of a 52 week blinded treatment period in Northeast Asia (China, Japan, Korea) which was followed by an optional open-label (OL) extension period in China for evaluation of belimumab in participants (par.) with active systemic lupus erythematosus (SLE).</recruitment_details>
      <pre_assignment_details>A total of 707 par. were randomized, 705 received at least 1 dose of investigational product (Safety Population), 677 par. were included in the primary efficacy population (MITT Population) of which 663 were evaluable for the primary endpoint. The participant flow and baseline characteristics are presented for MITT Population (Pop).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 milligrams (mg)/kilogram (kg) up to Year 5 Week 28.</description>
        </group>
        <group group_id="P2">
          <title>Belimumab 10 mg/kg</title>
          <description>Participants received belimumab 10 mg/kg IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 mg/kg up to Year 5 Week 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind (DB) Phase (52 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
                <participants group_id="P2" count="451"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="170"/>
                <participants group_id="P2" count="372"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol Defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Phase (Up to Year 5 Week 44)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134">Only eligible China par. enrolled in OL phase from MITT + additional 9 China par. from Safety Pop</participants>
                <participants group_id="P2" count="290">Only eligible China par. enrolled in OL phase from MITT + additional 16 China par. from Safety Pop</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="146"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Recorded</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 milligrams (mg)/kilogram (kg) up to Year 5 Week 28.</description>
        </group>
        <group group_id="B2">
          <title>Belimumab 10 mg/kg</title>
          <description>Participants received belimumab 10 mg/kg IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 mg/kg up to Year 5 Week 28.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="226"/>
            <count group_id="B2" value="451"/>
            <count group_id="B3" value="677"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.7" spread="9.18"/>
                    <measurement group_id="B2" value="32.3" spread="9.65"/>
                    <measurement group_id="B3" value="32.1" spread="9.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="419"/>
                    <measurement group_id="B3" value="629"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian - Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="403"/>
                    <measurement group_id="B3" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Japanese Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian - Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase.</title>
        <description>SRI response is a composite index, defined as the percent of participants with &gt;=4 point reduction from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score and no worsening (increase of &lt; 0.30 points from Baseline) in physicians global assessment (PGA) and no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).</description>
        <time_frame>Week 52</time_frame>
        <population>Modified Intention-to-Treat (MITT) Population: all participants who were randomized and treated with at least one dose of study treatment, with exclusion of participants from the site 086485.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 milligrams (mg)/kilogram (kg) up to Year 5 Week 28.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 10 mg/kg</title>
            <description>Participants received belimumab 10 mg/kg IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 mg/kg up to Year 5 Week 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response Rate at Week 52 for Double-blind Phase.</title>
          <description>SRI response is a composite index, defined as the percent of participants with &gt;=4 point reduction from Baseline in safety of estrogen in lupus national assessment (SELENA) systemic lupus erythematosus disease activity index (SLEDAI) score and no worsening (increase of &lt; 0.30 points from Baseline) in physicians global assessment (PGA) and no new British isles lupus assessment group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).</description>
          <population>Modified Intention-to-Treat (MITT) Population: all participants who were randomized and treated with at least one dose of study treatment, with exclusion of participants from the site 086485.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="446"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.1"/>
                    <measurement group_id="O2" value="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.40</ci_lower_limit>
            <ci_upper_limit>2.82</ci_upper_limit>
            <estimate_desc>Odds Ratio (95% CI) and p-value were estimated by a logistic regression model with independent variables treatment group, country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement (C) levels (low C3 and/or C4 vs. no low C3 or C4).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With &gt;=4 Point Reduction From Baseline in SELENA SLEDAI Score at Week 52 for Double-blind Phase.</title>
        <description>The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. The Baseline value of a variable is defined as the value of the variable measured at Day 0 prior to dosing. In case of multiple results on Day 0 prior to dosing, the latest result was used. If a Day 0 value was not available, the last available value prior to Day 0 was used.</description>
        <time_frame>Baseline (Day 0) and Week 52</time_frame>
        <population>MITT Population. Only those participants available at the specified time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 milligrams (mg)/kilogram (kg) up to Year 5 Week 28.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 10 mg/kg</title>
            <description>Participants received belimumab 10 mg/kg IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 mg/kg up to Year 5 Week 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With &gt;=4 Point Reduction From Baseline in SELENA SLEDAI Score at Week 52 for Double-blind Phase.</title>
          <description>The SELENA SLEDAI score is a weighted index for assessing SLE disease activity in which signs and symptoms, laboratory tests and physician's assessment for each of 9 organ system were given a weighted score and summed if present at the time of the visit or in the preceding 10 days. A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. A decrease of 4 points or more equates to a clinically meaningful improvement. The Baseline value of a variable is defined as the value of the variable measured at Day 0 prior to dosing. In case of multiple results on Day 0 prior to dosing, the latest result was used. If a Day 0 value was not available, the last available value prior to Day 0 was used.</description>
          <population>MITT Population. Only those participants available at the specified time points were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
                <count group_id="O2" value="447"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                    <measurement group_id="O2" value="55.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.41</ci_lower_limit>
            <ci_upper_limit>2.83</ci_upper_limit>
            <estimate_desc>Odds Ratio (95% CI) and p-value were estimated by a logistic regression model with independent variables treatment group, country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With SRI7 Response at Week 52 for Double-blind Phase.</title>
        <description>SRI7 response is defined as the percent of participants with &gt;=7 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of &lt; 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).</description>
        <time_frame>Baseline (Day 0) and Week 52</time_frame>
        <population>MITT Population. Only those participants available at the specified time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 milligrams (mg)/kilogram (kg) up to Year 5 Week 28.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 10 mg/kg</title>
            <description>Participants received belimumab 10 mg/kg IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 mg/kg up to Year 5 Week 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants With SRI7 Response at Week 52 for Double-blind Phase.</title>
          <description>SRI7 response is defined as the percent of participants with &gt;=7 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of &lt; 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at the time of assessment (at Week 52 of the blinded period). A SELENA SLEDAI score of 0 would suggest no lupus activity; while a score of 105 is the maximum calculable if all items were scored as being present from active lupus. PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range. The higher thresholds of SELENA SLEDAI improvement (i.e., SRI5, SRI6, and SRI7) indicates a higher response (SRI5 is a 5 point SELENA SLEDAI reduction, SRI6 is a 6 point reduction, and SRI7 is a 7 point reduction).</description>
          <population>MITT Population. Only those participants available at the specified time point were analyzed.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="367"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0116</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
            <estimate_desc>Odds Ratio (95% CI) and p-value were estimated by a logistic regression model with independent variables treatment group, country, baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days of Daily Prednisone Dose &lt;=7.5 mg/Day and/or Reduced by 50 Percent From Baseline Over 52 Weeks for Double-blind Phase.</title>
        <description>Number of days of daily prednisone dose &lt;=7.5 mg/day and/or reduced by 50 percent over time through each scheduled visit during the blinded period were compared between belimumab and placebo using Rank ANCOVA model which was used for comparing belimumab and placebo. The independent variables in the model included treatment group, Baseline prednisone dose level, country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). This analysis was perfomed on the participants who used prednisone &gt;7.5 mg/day at Baseline.</description>
        <time_frame>Week 52</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 milligrams (mg)/kilogram (kg) up to Year 5 Week 28.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 10 mg/kg</title>
            <description>Participants received belimumab 10 mg/kg IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 mg/kg up to Year 5 Week 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days of Daily Prednisone Dose &lt;=7.5 mg/Day and/or Reduced by 50 Percent From Baseline Over 52 Weeks for Double-blind Phase.</title>
          <description>Number of days of daily prednisone dose &lt;=7.5 mg/day and/or reduced by 50 percent over time through each scheduled visit during the blinded period were compared between belimumab and placebo using Rank ANCOVA model which was used for comparing belimumab and placebo. The independent variables in the model included treatment group, Baseline prednisone dose level, country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4). This analysis was perfomed on the participants who used prednisone &gt;7.5 mg/day at Baseline.</description>
          <population>MITT Population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="172.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="213.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0288</p_value>
            <method>Rank ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe SLE Flare Index (SFI) Flare Over 52 Weeks for Double-blind Phase.</title>
        <description>Time to first severe SLE flare is defined as the number of days from first treatment until the participant had an event (event date-treatement start date +1). If a participant had a severe SFI flare and received protocol restricted medication then the event date was the earliest of the first severe SFI flare date, and the treatment failure date. Analysis of severe SFI flare was performed on the modified SELENA SLEDAI SLE flare index in which the modification excluded severe flares that were triggered only by an increase in SELENA SLEDAI score to &gt;12. Analysis was from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4).</description>
        <time_frame>52 weeks</time_frame>
        <population>MITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 milligrams (mg)/kilogram (kg) up to Year 5 Week 28.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 10 mg/kg</title>
            <description>Participants received belimumab 10 mg/kg IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the double-blind period. All China participants who completed double-blind period and eligible to enter open-label phase received belimumab 10 mg/kg up to Year 5 Week 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe SLE Flare Index (SFI) Flare Over 52 Weeks for Double-blind Phase.</title>
          <description>Time to first severe SLE flare is defined as the number of days from first treatment until the participant had an event (event date-treatement start date +1). If a participant had a severe SFI flare and received protocol restricted medication then the event date was the earliest of the first severe SFI flare date, and the treatment failure date. Analysis of severe SFI flare was performed on the modified SELENA SLEDAI SLE flare index in which the modification excluded severe flares that were triggered only by an increase in SELENA SLEDAI score to &gt;12. Analysis was from Cox proportional hazards model for the comparison between belimumab and placebo adjusting for country, Baseline SELENA SLEDAI score (&lt;=9 vs. &gt;=10) and complement levels (low C3 and/or C4 vs. no low C3 or C4).</description>
          <population>MITT Population</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="226"/>
                <count group_id="O2" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Due to low event rates of participants in both treatment groups having severe SFI flares, the median time and interquartile range could not be estimated.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Due to low event rates of participants in both treatment groups having severe SFI flares, the median time and interquartile range could not be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>Regression, Cox</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving SLE SRI Response Rate for Open-label (OL) Phase</title>
        <description>SRI response is a composite index, defined as the percent of participants with &gt;=4 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of &lt; 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at time of assessment. Excludes participants with a SELENA SLEDAI score &lt;4 at baseline. Participants randomized to belimumab in double-blinded (DB) phase, Baseline is last available value before first belimumab dose received in DB phase. Participants randomized to placebo in DB phase, Baseline is last available value before receiving first belimumab dose in OL phase. Observed case data are presented.Year 6 Week 48 is the Exit Visit obtained by slotting the Exit Visit to Week 48. A SELENA SLEDAI score of 0 (no lupus activity) and a score of 105 (maximum). PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range.</description>
        <time_frame>Weeks 24 and 48 for Years 2, 3, 4, 5 and 6</time_frame>
        <population>Efficacy Population: all participants in China who received at least 1 dose of belimumab during open-label phase, exclusive of site 086485. Only those participants available at the specified time points were analyzed (represented by n=x).</population>
        <group_list>
          <group group_id="O1">
            <title>Belimumab 10mg/kg (Open-label Phase)</title>
            <description>All eligible China participants who had received placebo and belimumab in DB period and entered open-label phase to receive belimumab 10 mg/kg over 1 hour every 28 days from first belimumab date through end of open-label phase.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving SLE SRI Response Rate for Open-label (OL) Phase</title>
          <description>SRI response is a composite index, defined as the percent of participants with &gt;=4 point reduction from Baseline in SELENA SLEDAI score and no worsening (increase of &lt; 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline at time of assessment. Excludes participants with a SELENA SLEDAI score &lt;4 at baseline. Participants randomized to belimumab in double-blinded (DB) phase, Baseline is last available value before first belimumab dose received in DB phase. Participants randomized to placebo in DB phase, Baseline is last available value before receiving first belimumab dose in OL phase. Observed case data are presented.Year 6 Week 48 is the Exit Visit obtained by slotting the Exit Visit to Week 48. A SELENA SLEDAI score of 0 (no lupus activity) and a score of 105 (maximum). PGA ranges from 0 (no activity) to 3 (severe activity). BILAG has no range.</description>
          <population>Efficacy Population: all participants in China who received at least 1 dose of belimumab during open-label phase, exclusive of site 086485. Only those participants available at the specified time points were analyzed (represented by n=x).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="399"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24, Year 2, n=326</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Year 2, n=299</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Year 3, n=271</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="271"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Year 3, n=247</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Year 4, n=233</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="233"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Year 4, n=194</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="194"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Year 5, n= 156</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Year 5, n= 82</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, Year 6, n= 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, Year 6, n= 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-SAEs were collected from study treatment start and until 16 weeks after the last infusion. The data presented for belimumab open-label group represents safety events period starting from the first belimumab date and up to Year 6 Week 44.</time_frame>
      <desc>SAEs and non-serious AEs were reported for the Safety Population consisted of all participants who received at least one dose of study drug. The first belimumab date was first dose received in DB phase for participants randomized to belimumab in DB phase; first dose received in OL phase for participants randomized to placebo in DB phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Double-blind Phase)</title>
          <description>Participants received placebo intravenously (IV) on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the blinded period.</description>
        </group>
        <group group_id="E2">
          <title>Belimumab 10 mg/kg (Double-blind Phase)</title>
          <description>Participants received belimumab 10 miligrams (mg)/kilogram (kg) IV on Day 0, Day 14, Day 28 and then every 28 days until Week 48 of the blinded period.</description>
        </group>
        <group group_id="E3">
          <title>Belimumab 10 mg/kg (Open-label Phase)</title>
          <description>All eligible China participants who had received placebo and belimumab in DB period and entered open-label phase to receive belimumab 10 mg/kg over 1 hour every 28 days from first belimumab date through end of open-label phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="96" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Histiocytosis haematophagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Haemolytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 21.1">Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 21.1">Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Allergic colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lupus pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Intestinal pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Salmonella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Arthritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Bacterial pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cellulitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Gastrointestinal fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Spleen tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Tuberculosis liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Periorbital infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Ludwig angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Cutaneous tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Bartholin's abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Scapula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Lip injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SLE arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Loose body in joint</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Fibroadenoma of breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Benign ear neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Benign renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Haemangioma of liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Vaginal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Neuropsychiatric lupus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Noninfectious myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Foetal growth restriction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Post-traumatic stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lupus cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Bartholin's cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Endometrial thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lupus pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lupus pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Lupus vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="207" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="263" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="149" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="424"/>
              </event>
              <event>
                <sub_title vocab="MedDRA 21.1">Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 21.1">Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="235"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="470"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="424"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The primary objective for DB was efficacy and the participant flow is aligned with the MITT population. The primary objective for OL is safety and includes only China par. from DB + additional 25 China par. from the Safety Pop who were not in MITT.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

